Your browser doesn't support javascript.
loading
Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study.
Qian, Siyuan; Chen, Jun; Zhao, Yongchun; Zhu, Xiuxiu; Dai, Depeng; Qin, Lei; Hong, Juan; Xu, Yanming; Yang, Zhi; Li, Yunyan; Guijo, Ismael; Jiménez-Galanes, Santos; Guadalajara, Héctor; García-Arranz, Mariano; García-Olmo, Damián; Shen, Junjie; Villarejo-Campos, Pedro; Qian, Cheng.
Afiliação
  • Qian S; Department of Surgery, Fundación Jiménez Díaz University Hospital, Madrid, Spain. Electronic address: siyuanqz@gmail.com.
  • Chen J; Chongqing Key Laboratory of Gene and Cell Therapy, Chongqing Precision Biotechnology Co Ltd, Chongqing, China.
  • Zhao Y; Chongqing Key Laboratory of Gene and Cell Therapy, Chongqing Precision Biotechnology Co Ltd, Chongqing, China.
  • Zhu X; Chongqing Key Laboratory of Gene and Cell Therapy, Chongqing Precision Biotechnology Co Ltd, Chongqing, China.
  • Dai D; Chongqing Key Laboratory of Gene and Cell Therapy, Chongqing Precision Biotechnology Co Ltd, Chongqing, China.
  • Qin L; Chongqing Key Laboratory of Gene and Cell Therapy, Chongqing Precision Biotechnology Co Ltd, Chongqing, China.
  • Hong J; Chongqing Key Laboratory of Gene and Cell Therapy, Chongqing Precision Biotechnology Co Ltd, Chongqing, China.
  • Xu Y; Chongqing Key Laboratory of Gene and Cell Therapy, Chongqing Precision Biotechnology Co Ltd, Chongqing, China.
  • Yang Z; Chongqing Key Laboratory of Gene and Cell Therapy, Chongqing Precision Biotechnology Co Ltd, Chongqing, China.
  • Li Y; Chongqing Key Laboratory of Gene and Cell Therapy, Chongqing Precision Biotechnology Co Ltd, Chongqing, China.
  • Guijo I; Department of Surgery, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
  • Jiménez-Galanes S; Department of Surgery, University Hospital Infanta Elena, Madrid, Spain.
  • Guadalajara H; Department of Surgery, Fundación Jiménez Díaz University Hospital, Madrid, Spain; Department of Surgery, Universidad Autónoma de Madrid, Madrid, Spain.
  • García-Arranz M; Department of Surgery, Fundación Jiménez Díaz University Hospital, Madrid, Spain; Department of Surgery, Universidad Autónoma de Madrid, Madrid, Spain.
  • García-Olmo D; Department of Surgery, Fundación Jiménez Díaz University Hospital, Madrid, Spain; Department of Surgery, Universidad Autónoma de Madrid, Madrid, Spain.
  • Shen J; Chongqing Key Laboratory of Gene and Cell Therapy, Chongqing Precision Biotechnology Co Ltd, Chongqing, China. Electronic address: chris.shen@precision-biotech.com.
  • Villarejo-Campos P; Department of Surgery, Fundación Jiménez Díaz University Hospital, Madrid, Spain; Department of Surgery, Universidad Autónoma de Madrid, Madrid, Spain. Electronic address: pedro.villarejo@quironsalud.es.
  • Qian C; Chongqing Key Laboratory of Gene and Cell Therapy, Chongqing Precision Biotechnology Co Ltd, Chongqing, China. Electronic address: cqian8634@gmail.com.
Cytotherapy ; 26(2): 113-125, 2024 Feb.
Article em En | MEDLINE | ID: mdl-37999667
BACKGROUND AIMS: Peritoneal carcinomatosis (PC) from colorectal cancer (CRC) is a highly challenging disease to treat. Systemic chimeric antigen receptor (CAR) T cells have shown impressive efficacy in hematologic malignancies but have been less effective in solid tumors. We explored whether intraperitoneal (i.p.) administration of CAR T cells could provide an effective and robust route of treatment for PC from CRC. METHODS: We generated second-generation carcinoembryonic antigen (CEA)-specific CAR T cells. Various animal models of PC with i.p. and extraperitoneal metastasis were treated by i.p. or intravenous (i.v.) administration of CEA CAR T cells. RESULTS: Intraperitoneally administered CAR T cells exhibited superior anti-tumor activity compared with systemic i.v. cell infusion in an animal model of PC. In addition, i.p. administration conferred a durable effect and protection against tumor recurrence and exerted strong anti-tumor activity in an animal model of PC with metastasis in i.p. or extraperitoneal organs. Moreover, compared with systemic delivery, i.p. transfer of CAR T cells provided increased anti-tumor activity in extraperitoneal tumors without PC. This phenomenon was further confirmed in an animal model of pancreatic carcinoma after i.p. administration of our newly constructed prostate stem cell antigen-directed CAR T cells. CONCLUSIONS: Taken together, our data suggest that i.p. administration of CAR T cells may be a robust delivery route for effective treatment of cancer.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Peritoneais / Neoplasias Colorretais / Receptores de Antígenos Quiméricos Limite: Animals Idioma: En Revista: Cytotherapy Assunto da revista: TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Peritoneais / Neoplasias Colorretais / Receptores de Antígenos Quiméricos Limite: Animals Idioma: En Revista: Cytotherapy Assunto da revista: TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article